The invention behind this project is a new generation of extracorporeal photopheresis (ECP) using a novel combination of apheresis, a photosensitizer precursor (ALA) and LED light device (ALA-ECP). The method delivers autologously modulated T- cells to patients with T-cell mediated diseases. The concept has since 2014 attracted funding for academic development, and a first-in-man study has been completed with successful results. The main outcome of the qualification project was the improvement and refinement of the commercialization strategy. To commercialize a new method by depending on re-design of existing devices, owned by other manufacturers, is a challenging business model for a stand-alone venture. To be able to implement the new treatment method, we have decided to develop a novel medical device that is optimized to deliver ALA-ECP. The new drug-device combination will thus be a tangible product that can be patented, developed and commercialized by a start-up company.
ALA-ECP has a great potential to treat patients with immune diseases more safely and effectively than current second line treatment options. Further, the new, novel illumination device will allow for more widespread use of photopheresis. The main outcome of this project was a refinement of the commercialization strategy for ALA-ECP that will serve as a basis for a potential start-up establishment. A start-up company will have a great societal impact for the health industry in Norway. The new ALA-ECP medical device will have a great impact for the health care and patients by providing a new solution to treat immune diseases.